| αHBe | Antibody against Hepatitis Be Antigen |
|---|---|
| αHBs | Antibody against Hepatitis B surface Antigen |
| AVH | Acute Viral hepatitis |
| CAH | 1) Chronic Active Hepatitis 2) Congenital Adrenal Hyperplasia |
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| poliomyelitis vaccines | Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine. See: Salk vaccine. (05 Mar 2000) |
|---|---|
| poliovirus vaccines | Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine. See: Salk vaccine. (05 Mar 2000) |
| haemophilus vaccines | Vaccines or candidate vaccines containing antigenic polysaccharides from haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine. (12 Dec 1998) |
| saids vaccines | Vaccines or candidate vaccines designed to prevent saids (simian acquired immunodeficiency syndrome) and containing inactivated siv or type d retroviruses or some of their component antigens. (12 Dec 1998) |
| protozoan vaccines | Suspensions of attenuated or killed protozoa administered for the prevention or treatment of infectious protozoan disease. (12 Dec 1998) |
| hog cholera vaccines | Vaccine's either of virus from blood of infected swine, inactivated with crystal violet, or live virus attenuated in rabbits or tissue culture and frequently used in conjunction with hog cholera virus antiserum. (05 Mar 2000) |
| influenza virus vaccines | Influenza virus grown in embryonated eggs and inactivated, usually by the addition of formalin; both whole virus and subunit preparations containing haemagglutinins and neuraminidase are used; because of the marked and progressive antigenic variation of the influenza viruses, the strains included are regularly changed following various outbreaks of influenza in order to include most recently isolated epidemic strains of both type A influenza and type B influenza. (05 Mar 2000) |
| foot-and-mouth disease virus vaccines | Vaccine's either of inactivated virus from infected cattle tongue epithelium or, more recently, of live virus attenuated by embryonated egg or mouse passage and propagated in tissue culture. (05 Mar 2000) |
| fungal vaccines | Suspensions of attenuated or killed fungi administered for the prevention or treatment of infectious fungal disease. (12 Dec 1998) |
| live vaccines | Vaccines containing living organisms or intact viruses. (14 Nov 1997) |
| acute parenchymatous hepatitis | A lesion in which there is extensive and rapid death of parenchymal cells of the liver, sometimes with fatty degeneration of the size of the organ; the necrosis may result from fulminant viral infection or chemical poisoning; associated with jaundice. Synonym: acute parenchymatous hepatitis, Rokitansky's disease. (05 Mar 2000) |
| anicteric hepatitis | Hepatitis without jaundice. (05 Mar 2000) |
| anicteric virus hepatitis | A relatively mild hepatitis, without jaundice, due to a virus; the principal physical signs and symptoms are enlargement of the liver, lymph nodes, and often the spleen, together with headache, continuous fatigue, nausea, anorexia, sudden distaste for smoking, abdominal pains, and sometimes mild fever; labratory tests reveal evidence of hepatitis. (05 Mar 2000) |
| autoimmune hepatitis | <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver. Symptoms are those of chronic active hepatitis. (27 Sep 1997) |
| vaccination, hepatitis a | When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. (12 Dec 1998) |